Biotech Co. Inflated Gene Therapy Prospects, Investors Claim
Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...To view the full article, register now.
Already a subscriber? Click here to view full article